Read online here:
News | Calzone and Associates, Inc.
Friday, March 31, 2017
Taste of EatLafayette Moves To Cajundome Convention Center. Annual Event Features Louisiana Seafood Promotion Board Cook-Off.
Read more here: News | Calzone and Associates, Inc.
Tuesday, March 14, 2017
Wednesday, March 1, 2017
March 01, 2017
FOR IMMEDIATE RELEASE February 28, 2017
Thomas J. Concannon, CEO
G. Darcy Klug, Chairman and CFO
REDHAWK COMMENCES SALE OF BRANDED GENERICS TO CLINICAL COMMISSIONING GROUPS
Youngsville, Louisiana – RedHawk Holdings Corp. (OTCQB: IDNG) (“RedHawk” or the “Company”) announced today that EcoGen Europe Limited (“EcoGen”) has commenced the process of selling its branded generic pharmaceutical drugs to a Clinical Commissioning Group (“CCG”). Initial deliveries of EcoGen’s branded generics to this first CCG are expected to commence during March 2017. There are currently 212 CCG’s and the Company believes more CCG’s will begin taking delivery of EcoGen’s branded generics in the coming months.
CCG’s are organizations set up in the United Kingdom by the National Health Service (“NHS”) to organize the delivery of NHS services throughout England. They are clinically led groups that include all general practitioners in their geographic area. The aim of this structure is to give general practitioners and other clinicians the power to influence commissioning decisions for their patients. CCG’s are overseen by the NHS and operate by commissioning or buying healthcare services including pharmaceuticals, elective hospital care, rehabilitation care, urgent and emergency care and most community health services. CCG’s work with patients and healthcare professionals in partnership with local communities and authorities.
# # #
About RedHawk Holdings Corp.
RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the Sharps and Needle Destruction Device (SANDD™), the Carotid Artery Digital Non-Contact Thermometer and Zonis®. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk’s real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company’s financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner.
Cautionary Statement Regarding Forward Looking Statements
This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words “anticipate,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be,” “potential” and any similar expressions are intended to identify those assertions as forward-looking statements.
Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the “Risk Factors” section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.